PML and acute myeloid leukemia: For example, in acute promyelocytic leukemia (a distinct AML subtype), treatment with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) achieves high cure rates by targeting the PML-RARα fusion oncoprotein for degradation.